Nespo

RSS

darbepoetin alfa

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Nespo has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 28/01/2009

Authorisation details

Product details
Name
Nespo
Agency product number
EMEA/H/C/000333
Active substance
darbepoetin alfa
International non-proprietary name (INN) or common name
darbepoetin alfa
Therapeutic area (MeSH)
  • Kidney Failure, Chronic
  • Anemia
  • Cancer
Anatomical therapeutic chemical (ATC) code
B03XA02
Publication details
Marketing-authorisation holder
Dompé Biotec S.p.A.
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
08/06/2001
Contact address
Via San Martino 12
I-20122 Milan
Italy

Product information

28/10/2008 Nespo - EMEA/H/C/000333 - II/0047

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANTIANEMIC PREPARATIONS

Therapeutic indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Assessment history

How useful was this page?

Add your rating